Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association.
Level 5 - mechanism / opinion, no new human data
AHA Science Advisory / narrative expert review summarizing trial evidence
PubMed 31422671 · doi:10.1161/CIR.0000000000000709
What was done
The American Heart Association evaluated updated scientific data on the lipid, lipoprotein, and cardiovascular effects of pharmacological doses of prescription omega-3 fatty acids (EPA+DHA or EPA alone at >3 g/d, specifically 4 g/d) used as monotherapy or adjuncts to statins in patients with moderate hypertriglyceridemia (200–499 mg/dL) and very high triglycerides (≥500 mg/dL).
What was found
For very high triglycerides (≥500 mg/dL), 4 g/d of EPA+DHA reduced triglycerides by ≥30% with concurrent increases in LDL cholesterol, whereas EPA-only formulations did not raise LDL cholesterol. In moderate hypertriglyceridemia (200–499 mg/dL), EPA+DHA and EPA-only formulations provided comparable triglyceride lowering without raising LDL cholesterol, whether used alone or with a statin. Across large 4 g/d trials, non-HDL cholesterol and apolipoprotein B were modestly decreased. In the REDUCE-IT trial, 4 g/d of EPA-only reduced major adverse cardiovascular events by 25% in high-risk patients on statin therapy.
Why it matters
This advisory clarifies that high-dose prescription omega-3 fatty acids effectively lower triglycerides and total atherogenic lipoproteins, providing evidence-based guidance on formulation differences (EPA vs. EPA+DHA) regarding LDL cholesterol and cardiovascular event reduction.
Limits
The abstract represents a consensus advisory rather than an original trial or systematic review. Exact numerical changes for non-HDL cholesterol, apolipoprotein B, and moderate triglyceride lowering are not provided in the abstract, and cardiovascular outcome trial results for 4 g/d EPA+DHA were pending at the time of publication.
Cited by
- supports A daily intake of 3 grams of omega-3 fatty acids generally raises red blood cell omega-3 levels from 4% to 8%, and the standard pharmaceutical treatment dose is about 4 grams per day.